Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

rozanolixizumab 10 zilucoplan 8 efgartigimod alfa 8 Rituximab 7 Cyclophosphamide 7 telitacicept 6 fludarabine 6 eculizumab 5 Prednisone 5 ravulizumab 4 Pyridostigmine Bromide 4 Immunoglobulins, Intravenous 4 Hizentra 4 Tacrolimus 3 Mycophenolic Acid 3 HBM9161 3 Amifampridine 3 thymoglobulin 2 inebilizumab 2 Prednisolone 2 Exercise 2 tofacitinib 1 tocilizumab 1 talquetamab 1 satralizumab 1 sargramostim 1 rhoA GTP-Binding Protein 1 remibrutinib 1 prednylidene 1 iscalimab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Myasthenia Gravis × remibrutinib × Clear all

NCT06744920 2026-06-01

RELIEVE

Novartis

Phase 3 Recruiting

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡